A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.

Market Analysis and Insights: Global Acute Migraine Drugs Market
In 2020, the global Acute Migraine Drugs market size was US$ 1956.9 million and it is expected to reach US$ 3211.7 million by the end of 2027, with a CAGR of 7.3% between 2021 and 2027
Global Acute Migraine Drugs Scope and Market Size
The global Acute Migraine Drugs market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Acute Migraine Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.

Segment by Type
Triptans
NSAIDs
Others
The proportion of triptans in 2019 is about 79.59% market share.

Segment by Application
Hospital Pharmacies
Drug Stores
The proportion of hospitals in 2019 is about 62.93%.

By Company
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE